|
Because the CYPHER® Sirolimus-eluting Coronary Stent contains sirolimus, it significantly reduces the risk of re-blockage in the treated area and the need for another procedure.
A study called the SIRIUS trial was conducted to compare the CYPHER® Stent with an uncoated stent. After nine months, re-blockage within the stent occurred in significantly fewer patients who received the CYPHER® Stent than in those who had received the uncoated stent. The overall risks associated with the CYPHER® Stent are similar to the risks associated with uncoated stents.
Before you decide on a treatment, you should discuss all of the options with your doctor. Only he or she knows which option would be the best for you. To help you feel comfortable discussing these issues, you can print the Questions to Ask Your Doctor or read the Important Product Information |